WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H561299
CAS#: 31750-48-8 (free base)
Description: N-Desmethyltamoxifen is the primary metabolite of tamoxifen. It is an estrogen response modifer and protein kinase C inhibitor.
Hodoodo Cat#: H561299
Name: N-Desmethyltamoxifen
CAS#: 31750-48-8 (free base)
Chemical Formula: C25H27NO
Exact Mass: 357.21
Molecular Weight: 357.500
Elemental Analysis: C, 83.99; H, 7.61; N, 3.92; O, 4.48
Related CAS #: 31750-48-8 (free base) 15917-65-4 (HCl)
Synonym: N-Desmethyltamoxifen; Desmethyltamoxifen; ICI-55548;
IUPAC/Chemical Name: 2-[4-[(Z)-1,2-Diphenylbut-1-enyl]phenoxy]-N-methylethanamine
InChi Key: NYDCDZSEEAUOHN-IZHYLOQSSA-N
InChi Code: InChI=1S/C25H27NO/c1-3-24(20-10-6-4-7-11-20)25(21-12-8-5-9-13-21)22-14-16-23(17-15-22)27-19-18-26-2/h4-17,26H,3,18-19H2,1-2H3/b25-24-
SMILES Code: CC/C(C1=CC=CC=C1)=C(C2=CC=C(OCCNC)C=C2)\C3=CC=CC=C3
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 357.50 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Ahern TP, Hertz DL, Damkier P, Ejlertsen B, Hamilton-Dutoit SJ, Rae JM, Regan MM, Thompson AM, Lash TL, Cronin-Fenton DP. Cytochrome P-450 2D6 (CYP2D6) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of Heterozygosity. Am J Epidemiol. 2017 Jan 15;185(2):75-85. doi: 10.1093/aje/kww178. Epub 2016 Dec 17. Review. PubMed PMID: 27988492; PubMed Central PMCID: PMC5253974.
2: Morad SA, Cabot MC. Tamoxifen regulation of sphingolipid metabolism--Therapeutic implications. Biochim Biophys Acta. 2015 Sep;1851(9):1134-45. doi: 10.1016/j.bbalip.2015.05.001. Epub 2015 May 9. Review. PubMed PMID: 25964209; PubMed Central PMCID: PMC4516673.
3: Jordan VC. New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer. Steroids. 2007 Nov;72(13):829-42. Epub 2007 Jul 27. Review. PubMed PMID: 17765940; PubMed Central PMCID: PMC2740485.
4: Goetz MP, Loprinzi CL. A hot flash on tamoxifen metabolism. J Natl Cancer Inst. 2003 Dec 3;95(23):1734-5. Review. PubMed PMID: 14652227.
5: White IN. Tamoxifen: is it safe? Comparison of activation and detoxication mechanisms in rodents and in humans. Curr Drug Metab. 2003 Jun;4(3):223-39. Review. PubMed PMID: 12769667.
6: Bachmann-Moisson N, Barberi-Heyob M, Merlin JL, Ledrich ML, Batt AM, Guillemin F. [Cytotoxicity of tamoxifen and its principal metabolites in human breast cancer cell lines]. Bull Cancer. 1996 Oct;83(10):808-15. Review. French. PubMed PMID: 8952630.
7: Pasqualini JR, Sumida C, Giambiagi NA, Nguyen BL. The complexity of anti-estrogen responses. J Steroid Biochem. 1987;27(4-6):883-9. Review. PubMed PMID: 3320567.
8: Jordan VC. Metabolites of tamoxifen in animals and man: identification, pharmacology, and significance. Breast Cancer Res Treat. 1982;2(2):123-38. Review. PubMed PMID: 6184101.